College of Pharmacy
Schmidt Lab
Led by Stephan Schmidt · Pharmaceutics
What we study
The Schmidt Lab develops and applies disease-drug-trial models to study chronic diseases, special patient populations, and drug interactions. They use mechanism-based models to address clinically relevant questions.
What working here is like
- Computational
- No organisms (data only)
- Coding required
- Projects
- 2
- Papers
- 5
Current projects
Pharmacology Modeling for Contraceptive Product Development
Builds pharmacology models that predict how contraceptive drugs behave in the body, to help guide the development of new products.
Development and verification of mechanism-based translational disease modeling platform for neurodegenerative disorders
Builds computer models that link disease biology and drug effects to study neurodegenerative disorders, creating a platform for testing treatment ideas.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- Model‐Informed Dose Selection of Intranasal Epinephrine in Young Children
2026 · The Journal of Clinical Pharmacology
Develops a model to set weight-based nasal epinephrine doses for young children.
- Exposure‐Matched Intranasal Epinephrine Dosing in Children Is Supported by Pharmacology, Pharmacodynamic Evidence, and Regulatory Review
2026 · The Journal of Clinical Pharmacology
Reviews evidence supporting weight-based nasal epinephrine doses for children.
Show 3 more papersShow fewer
- Mechanistic Prediction of Maternal, Fetal, and Amniotic Fluid Betamethasone Concentrations to Support Dosing Optimization in Pregnancy
2026 · The Journal of Clinical Pharmacology
Builds a model to predict how betamethasone doses affect fetal lung maturity in pregnancy.
- Mechanistic mass transport analysis of dissolution of weak-base drugs considering the influence of surface pH in formulations with and without acidifying agents
2026 · Frontiers in Pharmacology
Models how acid in pills affects how weak-base drugs dissolve in the gut.
- Bleeding and Thromboembolic Outcomes Following GLP ‐1 Receptor Agonist Initiation in Patients With Type 2 Diabetes and Atrial Fibrillation Receiving Direct Oral Anticoagulants: A Target Trial Emulation
2026 · Diabetes Obesity and Metabolism
Tests whether starting diabetes drugs in people with atrial fibrillation and diabetes raises bleeding or clotting risks.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Stephan Schmidt hasn't set up this page yet. You can also look them up in the UF directory (search “Stephan Schmidt”).